How can we improve the design of small molecules to target thioredoxin reductase for treating cancer?

Expert Opin Drug Discov. 2021 Apr;16(4):331-333. doi: 10.1080/17460441.2021.1854220. Epub 2020 Dec 14.

Authors

Jianqiang Xu¹, Jianguo Fang²

Affiliations

¹ School of Life and Pharmaceutical Sciences (LPS) and Panjin Institute of Industrial Technology (PIIT), Dalian University of Technology, Panjin, China.
² State Key Laboratory of Applied Organic Chemistry & College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China.

PMID: 33307863
DOI: 10.1080/17460441.2021.1854220

No abstract available

Keywords: Thioredoxin; cancer; covalent inhibitor; prodrug; redox regulation; selenocysteine.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology*
Drug Design
Enzyme Inhibitors / pharmacology
Humans
Neoplasms / drug therapy*
Neoplasms / enzymology
Thioredoxin-Disulfide Reductase / antagonists & inhibitors*
Thioredoxin-Disulfide Reductase / metabolism

Substances

Antineoplastic Agents
Enzyme Inhibitors
Thioredoxin-Disulfide Reductase